Search Results for "therapeutic"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

GRAPHICAL ABSTRACT: Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial

Real-World Persistency on Tafamidis: An Analysis of US Insurance Claims Data

Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

Health-related quality of life for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan

Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program

KARDIA-3: zilebesiran as add-on therapy in adults with hypertension who have established cardiovascular disease or are at high cardiovascular risk

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan

HELIOS-B 12-Month Results from the Open-Label Extension Period of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External

V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

Baseline Characteristics of Patients with ATTR Amyloidosis Enrolled into the ConTTRibute Registry

Real-World Treatment Patterns in Participants with Transthyretin Amyloidosis with Polyneuropathy Enrolled in the ConTTRibute Registry

A Phase 2 Study Evaluating the Effects of Mivelsiran, an Investigational RNA Interference Therapeutic, on Hemorrhagic and Nonhemorrhagic Manifestations of Cerebral Amyloid Angiopathy

Impact of Zilebesiran, an Investigational RNA Interference Therapeutic Targeting Hepatic Angiotensinogen, on Renin–Angiotensin System Biomarkers in Patients with Mild-to-Moderate Hypertension

RNAi Therapeutics: How Do They Work?

This video highlights the MOA of RNAi and how small interfering RNA (siRNA) are used to harness the RNA-induced silencing complex (RISC) to regulate gene expression. This resource is intended to be viewed in its entirety to support scientific exchange and is not intended as recommendations for clinical practice. For further information, please see RNAiScience.com to connect with a Medical Science Liaison, submit a medical information request, or access other Alnylam medical education resources.

RNAi Data Navigator: Focus on Vutrisiran

Use this interactive tool to learn more about ATTR, RNAi therapeutics, findings from the HELIOS B study in ATTR CM, findings from the HELIOS A study in hATTR PN, and Alnylam’s commitment to ATTR. HELIOS-B data include outcomes on survival, functional capacity, quality of life, CV events, exploratory measures of cardiac biomarkers, structure and function, post hoc extracardiac analyses, and safety. HELIOS-A data include outcomes on neuropathy impairment, quality of life, gait speed, nutritional status, disability, and safety. Navigate using the forward and backward controls. For optimal viewing, enter full-screen mode.

Summary of RNA Interference

An overview of RNAi discovery, how RNAi works, and features of RNAi therapeutics

The Science of RNA interference (RNAi)

This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Zilebesiran: Mechanism of Action

Standard response letter on the mechanism of action of zilebesiran.

Vutrisiran: Use with mRNA COVID-19 Vaccines

Standard response letter on use of mRNA COVID-19 vaccines in patients receiving vutrisiran.

ALN-HTT02: Phase 1b Study

Standard response letter on the phase 1 study of ALN-HTT02.

Vutrisiran: Technetium Scintigraphy

Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "therapeutic"

Summary of RNA Interference An overview of RNAi discovery, how RNAi works, and features of RNAi therapeutics

The Science of RNA interference (RNAi) This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Zilebesiran: Mechanism of Action Standard response letter on the mechanism of action of zilebesiran.

Vutrisiran: Use with mRNA COVID-19 Vaccines Standard response letter on use of mRNA COVID-19 vaccines in patients receiving vutrisiran.

ALN-HTT02: Phase 1b Study Standard response letter on the phase 1 study of ALN-HTT02.

Vutrisiran: Technetium Scintigraphy Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.